Zostavax

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
051020062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Background Population aging brings up a number of health issues, one of which is an increased incidence of herpes zoster (HZ) and… (More)
Is this relevant?
2015
2015
ZOSTAVAX(®) is a live attenuated varicella-zoster virus (VZV) vaccine that is licensed for the protection of individuals ≥50… (More)
Is this relevant?
2013
2013
INTRODUCTION Herpes zoster (HZ) occurs as a reactivation of dormant varicella zoster virus (VZV), and occurs more frequently in… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Herpes zoster (HZ) adversely affects individuals aged 50-59, but vaccine efficacy has not been assessed in this… (More)
Is this relevant?
2011
2011
Analysis of 36 individuals over age 60 years who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs… (More)
  • table 1
  • figure 1
Is this relevant?
2011
2011
Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2011
2011
INTRODUCTION Zostavax, a live attenuated vaccine, has been approved in the United States for use in older individuals to reduce… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2009
2009
Zostavax has been shown to be efficacious in the prevention of herpes zoster and generally well tolerated in clinical trials… (More)
Is this relevant?
2008
2008
The vaccine Zostavax has been shown to prevent herpes zoster (HZ) and postherpetic neuralgia and is recommended for individuals… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?